INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 242 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $375,188 | -19.3% | 5,478 | -18.4% | 0.00% | -50.0% |
| Q1 2024 | $464,816 | -67.4% | 6,717 | -66.3% | 0.00% | -60.0% |
| Q4 2023 | $1,427,172 | +2.5% | 19,927 | -25.4% | 0.01% | 0.0% |
| Q3 2023 | $1,391,949 | +17.1% | 26,722 | +42.3% | 0.01% | 0.0% |
| Q2 2023 | $1,189,150 | +284.9% | 18,780 | +229.2% | 0.01% | +400.0% |
| Q1 2023 | $308,926 | +1.4% | 5,705 | -0.9% | 0.00% | -50.0% |
| Q4 2022 | $304,714 | +444.1% | 5,758 | +485.2% | 0.00% | – |
| Q2 2022 | $56,000 | -8.2% | 984 | -2.1% | 0.00% | – |
| Q1 2022 | $61,000 | +29.8% | 1,005 | +10.9% | 0.00% | – |
| Q4 2021 | $47,000 | +88.0% | 906 | +34.2% | 0.00% | – |
| Q3 2021 | $25,000 | +4.2% | 675 | +15.4% | 0.00% | – |
| Q2 2021 | $24,000 | +20.0% | 585 | 0.0% | 0.00% | – |
| Q1 2021 | $20,000 | +100.0% | 585 | +95.0% | 0.00% | – |
| Q4 2020 | $10,000 | +25.0% | 300 | 0.0% | 0.00% | – |
| Q3 2020 | $8,000 | 0.0% | 300 | 0.0% | 0.00% | – |
| Q2 2020 | $8,000 | – | 300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| DCF Advisers, LLC | 375,000 | $15,308,000 | 5.42% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 113,258 | $4,623,000 | 2.06% |
| Tri Locum Partners LP | 150,783 | $6,155,000 | 2.02% |
| COOPER/HAIMS ADVISORS, LLC | 61,116 | $2,495,000 | 1.64% |
| Vantage Consulting Group Inc | 226,670 | $9,252,000 | 1.61% |
| Nicholas Investment Partners, LP | 598,261 | $24,421,000 | 1.53% |
| Bellevue Group AG | 3,609,919 | $147,357,000 | 1.44% |
| GENERAL AMERICAN INVESTORS CO INC | 350,804 | $14,320,000 | 1.20% |
| Rhenman & Partners Asset Management AB | 429,728 | $17,541,000 | 1.19% |
| WASATCH ADVISORS LP | 6,506,789 | $265,607,000 | 1.08% |